Remarkably, a single apheresis session was sufficient for collecting an adequate number of CD34+ cells for ASCT in 89.7% (n=35/39) of lymphoma patients, a significantly higher rate compared to reported outcomes with plerixafor (56.5%) (10). Here, CD34 is linked to lymphoma.